The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
MicroRNAs in Metabolic Disease
Open accessAbstract
Alterations in the metabolic control of lipid and glucose homeostasis predispose an individual to develop cardiometabolic diseases, such as type 2-diabetes mellitus and atherosclerosis. Work over the last years has suggested that microRNAs (miRNAs) play an important role in regulating these physiological processes. The contribution of miRNAs in regulating metabolism is exemplified by miR-33, an intronic miRNA encoded in the Srebp genes. miR-33 controls cellular cholesterol export and fatty acid degradation, whereas its host genes stimulate cholesterol and fatty acid synthesis. Other miRNAs, such as miR-122, also play a critical role in regulating lipid homeostasis by controlling cholesterol synthesis and lipoprotein secretion in the liver. This review article summarizes the recent findings in the field, highlighting the contribution of miRNAs in regulating lipid and glucose metabolism. We will also discuss how the modulation of specific miRNAs may be a promising strategy to treat metabolic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“microRNAs can alter the expression of genes in insulin-producing and insulin-sensitive tissues, including the pancreas, liver, and vasculature.”
From The Vasculature in Prediabetes (2018) · cites this paper as [134]
In the citing paper
“The most abundant microRNA in the liver is miR-122.”
From The Vasculature in Prediabetes (2018) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Wightman, B., Ha, I., & Ruvkun, G. (1993) · Cell · doi:10.1016/0092-8674(93)90530-4 · Cited by 4,292
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Arroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruf, I. K., Pritchard, C. C., Gibson, D. F., Mitchell, P. S., Bennett, C. F., Pogosova-Agadjanyan, E. L., Stirewalt, D. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019055108 · Cited by 3,294
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011) · Nature Cell Biology · doi:10.1038/ncb2210 · Cited by 2,741
A pancreatic islet-specific microRNA regulates insulin secretion
Poy, M. N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., MacDonald, P. E., Pfeffer, S., Tuschl, T., Rajewsky, N., Rorsman, P., et al. (2004) · Nature · doi:10.1038/nature03076 · Cited by 2,102
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082
LNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589
Cited by
Sorted by citations
Items 201–257 of 257
Ozfiliz-Kilbas, P., Sönmez, Ö., Yerlikaya, P. O., Gürkan, A. Ç., Palavan-Ünsal, N., Onganer, P. U., & Arısan, E. D. (2021) · Cancers · doi:10.3390/cancers13215322 · Cited by 6
“While the expression levels of SREBP2 were diminished in MDAMB-231 cells, AMPKα activation was apparent following miR-33a mimic treatment.”
InfluentialRecent advances in understanding the role of miRNAs in exosomes and their therapeutic potential
Miao, X. (2017) · Journal of Integrative Agriculture · doi:10.1016/s2095-3119(16)61530-7 · Cited by 6
Caria, A. C. I., Ferrari, F., Gomes, J. L. P., Villalta, P. B., Soci, Ú. P. R., Stein, R., & de Oliveira, E. M. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i6.1187 · Cited by 6
Quitete, F. T., de Moura, E. G., Peixoto, T. C., Torsoni, A. S., Torsoni, M. A., Milanski, M., Ignácio-Souza, L. M., Simino, L. A. D. P., OLIVEIRA, E. B. D., & Lisboa, P. C. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.103577 · Cited by 5
Aranda, J. F., Pérez-García, A., Torrecilla-Parra, M., Frutos, M. F.-D., Martín-Martín, Y., Mateos-Gómez, P. A., Pardo-Marqués, V., Busto, R., & Ramírez, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.994080 · Cited by 3
Self-citationMissae, L., Rossoni, B. P., Tenorio, E. R., Ribeiro, M. S., Tirapelli, D. P. D. C., & Joviliano, E. É. (2021) · Brazilian Journal of Cardiovascular Surgery · doi:10.21470/1678-9741-2020-0268 · Cited by 5
“Recent studies on their origin, biogenesis, and mechanisms of action have greatly increased the knowledge about their molecular biology[5].”
BackgroundMetabolic response to exercise in childhood brain tumor survivors: A pilot controlled study
Papalia, H., Rochette, E., Pereira, B., Merlin, É., Kanold, J., Duché, P., & the HERCCULE GROUP (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.28053 · Cited by 5
Ardekani, A. M., Kharazinejad, E., Ghasemi, E., Ghasemi, H., & Soltani, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28053 · Cited by 4
“…of gene expression at the post-transcriptional stages. miRNA is able to target the 3 ′ untranslated region (3 ′ UTR) of mRNAs and thereby suppress their translation [16,17]. miR-122 abundantly expressed in liver [18,19] and involved in the regulation of glucose and lipid metabolism [20,21].”
BackgroundMiR-363 suppresses the tumor growth of natural killer/T-cell lymphoma via the SIRT6/PI3K/AKT axis
Xu, B., Jiang, L., Cui, J.-L., Zhu, X.-L., Bai, Y., Chen, J., & Diao, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-5649 · Cited by 3
“Previously, numerous studies have demonstrated the key regulatory role of miRNAs in the pathogenesis of diseases, especially in cancer (7,8).”
Post-transcriptional and Post-translational Regulation of Steroidogenesis
Shen, W., Hu, Z., Hu, J., Kraemer, F. B., & Azhar, S. (2015) · Springer eBooks · doi:10.1007/978-3-319-25124-0_12 · Cited by 4
MicroRNAs in metabolic syndrome: Mechanisms, diagnosis, and therapy
Rahman, M. A., Islam, M. M., Islam, M. M., Ripon, M. A. R., & Hossain, M. S. (2025) · Advances in clinical chemistry · doi:10.1016/bs.acc.2025.06.003 · Cited by 4
Atteia, H. H. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010282155231222071903 · Cited by 3
Non-coding RNAs in alcohol-associated liver disease
Zeng, G., Gao, H., Jiang, Y., Huda, N., Thoudam, T., Yang, Z., Ma, J., Sun, J., & Liangpunsakul, S. (2025) · Liver Research · doi:10.1016/j.livres.2025.04.007 · Cited by 3
Joshua, J., Caswell, J., Kipar, A., O’Sullivan, M. L., Wood, G. A., & Fonfara, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146764 · Cited by 3
Ma, Y., Xing, X., Cheng, C., Kong, R., Sun, L., Zhao, F., Zhang, D., & Li, J. (2023) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2023.111832 · Cited by 3
Michell, D. L., Zhao, S., Allen, R. M., Sheng, Q., & Vickers, K. C. (2020) · Diabetes · doi:10.2337/dbi19-0015 · Cited by 4
“Although newmiRNA studies in glucose metabolism are still being reported and provide the basis for future drug therapies (3), many miRNA investigators have spread to the far corners of the RNA world in search of the next big thing.”
BackgroundmiRNA-122 as a new player in cardiovascular disease
Alieva, A. M., Teplova, N. V., Reznik, E. V., Baykova, I. E., Shnakhova, L. M., Гургеновна, Т. Г., Valiev, R. K., Skripnichenko, E. A., Kotikova, I. A., & Nikitin, I. G. (2023) · Russian Medicine · doi:10.17816/medjrf111180 · Cited by 2
Proanthocyanidins and Epigenetics
Bladé, C., Arola‐Arnal, A., Crescenti, A., Suárez, M., Bravo, F. I., Aragonès, G., Muguerza, B., & Arola, L. (2017) · Springer eBooks · doi:10.1007/978-3-319-31143-2_16-1 · Cited by 2
Brizzi, M. F. (2014) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.s1-022 · Cited by 2
“Recently, a miRNA signature in insulin target tissues and a plasma miRNA profile in type 2 diabetes have been reported [52].”
BackgroundPathogenetic mechanisms of statin dysglycemia and risk of new-onset diabetes
Pappa, M. B., Tsimihodimos, V., & Alaveras, A. (2021) · Journal of Atherosclerosis Prevention and Treatment · doi:10.53590/japt.02.1018 · Cited by 2
MicroRNAs in Cardiometabolic Diseases
Meiliana, A., & Wijaya, A. (2013) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v5i2.55 · Cited by 2
Farmer, L. M., & Hirschi, K. D. (2017) · Wiley eBooks · doi:10.1002/9781119101277.ch9 · Cited by 2
STATIN-INDUCED MECHANISMS OF CARBOHYDRATE METABOLISM DISORDERS
Никонова, Л. В., & Tishkovskiy, S. V. (2021) · Journal of the Grodno State Medical University · doi:10.25298/2221-8785-2021-19-2-147-152 · Cited by 1
Cardiometabolic Syndromes and Associated Cardiovascular Risks: A Narrative Review
Ruiz-Saavedra, A., Lara, F. V.-O. D., & Martínez, J. A. (2026) · Journal of Vascular Research · doi:10.1159/000549775 · Cited by 1
“Specific microRNAs, such as miR-33 and miR-122 impair the metabolic processing of lipids and carbohydrates, unlocking new possible treatment targets [101].”
Zanotto, T. M., & SAAD, M. J. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146501 · Cited by 1
“In obesity and T2DM, the dysregulation of specific miRNAs has been shown to alter insulin sensitivity in target tissues, such as the liver, skeletal muscle, and adipose tissue, thereby contributing to the development and progression of IR [10,11].”
Colon Epithelial MicroRNA Network in Fatty Liver
Joseph, P. V., Abey, S. K., Wang, D., Fourie, N. H., Kenea, N. D., Vishnyakova, T. G., Robinson, J. M., Weaver, K. R., Boulineaux, C. M., Davidson, H., et al. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/8246103 · Cited by 1
Clinical Potential of miRNAs in Human and Infectious Diseases
Haidar, M., & Langlsey, G. (2020) · Journal of Green Engineering · doi:10.13052/mct2052-8426.811 · Cited by 1
miRNAs activate mitochondrial energy metabolism: a narrative view
Nascimento, O. V., Cavalcante, K. S., da Silva, W. K. B., Nascimento, W., & Astolfi, S. (2023) · Concilium · doi:10.53660/clm-1475-23g02a · Cited by 1
Accurate Detection of MicroRNAs from NanoString nCounter with a Latent Mixture Model
Chang, Y., & Wu, Z. J. (2023) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm58861.2023.10385632 · Cited by 1
MicroRNAs as biomarkers in induced metabolic syndrome in rats
Al-Hayali, M. A., Hussein, A. A., & Mustafa, N. G. (2024) · Al-mağallaẗ al-ʻirāqiyyaẗ li-l-ʻulūm al-bayṭariyyaẗ/Iraqi journal of veterinary sciences · doi:10.33899/ijvs.2024.146755.3466 · Cited by 1
A Brief review of Circulating MicroRNAs and Essential Hypertension
Badawy, H., Mesbah, N. M., & Abo-elmatty, D. (2018) · Records of Pharmaceutical and Biomedical Sciences · doi:10.21608/rpbs.2018.5986.1016 · Cited by 1
Adipose Compounds in Breast Tumor Extracellular Matrix
Piccioni, F., & Luca, P. D. (2022) · Biology of extracellular matrix · doi:10.1007/978-3-030-99708-3_12 · Cited by 1
Reda, R. S., & Jabbar, N. K. (2024) · Military Medical Science Letters · doi:10.31482/mmsl.2023.020 · Cited by 1
Agudo, O., & Fernanda, L. (2015) · The Sydney eScholarship Repository (The University of Sydney) · Cited by 1
Expressão de microRNAs circulantes relacionados ao diabetes tipo 1 autoimune
Santos, A. S. (2018) · doi:10.11606/t.5.2018.tde-14082018-124100 · Cited by 1
Lagadinos, A. N. (2013) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/m2r88r
“Along these lines, unique miRNA expression profiles have been correlated with the manifestation of numerous diseases (94, 98, 144, 197, 208, 209, 337).”
Background‘Micro’-management of Obesity and Cancer
Mohanraj, L. (2013) · Postdoc Journal · doi:10.14304/surya.jpr.v1n6.1
“Differences in the role of miRNA have been shown in obese conditions versus normal, lean metabolic conditions, therefore showing the potential to be involved in obesity associated complications [89].”
BackgroundModulation of mir-33 and mir-122 by dietary polyphenols
Baselga‐Escudero, L. (2013) · TDX (Tesis Doctorals en Xarxa)
Γενετική διερεύνηση ανευρύσματος κοιλιακής αορτής
Μουρμούρα, Ε. (2016) · doi:10.12681/eadd/39065
Esteves, J. V. D. C. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2017.tde-17052017-164705
Patoulias, D. (2018) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2018.76823
“More specifically, it is crucial for cholesterol biosynthesis and very low-density lipoprotein (VLDL) secretion in the liver [3].”
BackgroundEpigenetic Biomarkers of Biological Age
Daimiel, L., & Micó, V. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.62147-5
Childhood leukemia survivors and metabolic response to exercise: A pilot controlled study
Pegon, C., Rochette, E., Rouel, N., Pereira, B., Doré, É., Isfan, F., Grèze, V., Merlin, É., Kanold, J., & Duché, P. (2020) · Yearbook of pediatric endocrinology · doi:10.1530/ey.17.9.10
The Mechanisms of miR-638/StarD10 in HDL MetabolismPreprint
Ye, P., Wang, X.-N., Han, J., Cao, R., & Bai, Y.-Y. (2021) · Research Square · doi:10.21203/rs.3.rs-142814/v1
“Not only can miRNAs be regulated at the posttranscriptional level, but they can also change the transduction of cell signals[50-60].”
BackgroundDaimiel, L. (2019) · Springer eBooks · doi:10.1007/978-3-319-55530-0_52 · Cited by 1
MicroRNAs and Pancreatic ß Cell Functional Modulation
Irfan, S., Jabeen, F., & Anwar, H. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105588
Diabetogenic action of statins — mechanisms and consequences. Review
Сергієнко, В. О., & Serhiyenko, O. (2022) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2022-2-69
Цукровий діабет, дисліпопротеїнемії та статини
Serhiyenko, V. A., & Serhiyenko, A. A. (2022) · Endokrynologia · doi:10.31793/1680-1466.2022.27-1.29
The Effect of Exercise Training on Circulating microRNAs Related to Lipid Metabolism
Kaya, K., Yerlikaya, F. H., Kürklü, G. B., & Onmaz, D. E. (2022) · Journal of Turkish Clinical Biochemistry · doi:10.56615/tkbd.2022.16
“126 Türk Klinik Biyokimya Derg 2022;20(3) diseases (11).”
BackgroundUnveiling the Health Impact: A Comprehensive Review of Ultra‐Processed Beverages
Ouyang, Y., Gao, Z., Tan, J., Liu, P., Xiao, Y., Wang, Y., Liu, J., Gao, B., Liu, B., & Zhu, D. (2025) · Journal of Food Science · doi:10.1111/1750-3841.70741
Mohany, K. M., Rugaie, O. A., Al-Wutayd, O., & Al‐Nafeesah, A. (2021) · Figshare · doi:10.6084/m9.figshare.15102736
Kolli, V., Trick, J., Schulman, A., Iben, J., Padilla, C. J., Li, T., Faucz, F. R., & Merke, D. P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1784619
“For example, dysregulation in speci fi c miRNAs can lead to changes in cell proliferation, tumor progression (12), and metabolic syndrome where lipid and glucose homeostasis are affected (13).”
MicroRNAs in metabolic syndrome and diabetes
Gupta, J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44591-0.00006-0
Srivastava, R. A. K. (2026) · Cells · doi:10.3390/cells15171575
“Clinical trials demonstrated that inclisiran produces ~50% sustained reductions in LDL-C with a dosing regimen of twice yearly following an initial loading phase [40,41,76].”
Metadata
- Authors
- Fernández-Hernando, C., Ramírez, C. M., Goedeke, L., & Suárez, Y.
- Affiliations
- From the Departments of Medicine and Cell Biology, Leon H. Charney Division of Cardiology and the Marc and Ruti Bell Vascular Biology and Disease Program, New York University School of Medicine, New York, NY.
- New York University (US)
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2013-02
- Volume
- 33
- Issue
- 2
- Pages
- 178-185
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- PMC
- PMC3740757
- OpenAlex
- W2042714431
- Cited by
- 257
- References
- 67
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 12 · 2023: 12 · 2022: 21 · 2021: 15 · 2020: 18 · 2019: 21 · 2018: 24 · 2017: 25 · 2016: 21 · 2015: 21 · 2014: 30 · 2013: 21
- FWCI
- 10.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL105945, R01HL106063, R01HL107953)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- microRNA, metabolic disorders, lipid homeostasis, glucose homeostasis, type 2 diabetes, atherosclerosis, miR-33, SREBP, miR-122, cholesterol biosynthesis, lipoprotein secretion, liver, cholesterol export, fatty acid degradation, miRNA-based therapy
- MeSH terms
- Animals, Gene Expression Regulation, Glucose, Homeostasis, Humans, Insulin, Metabolic Diseases, Genetic Therapy, Signal Transduction, MicroRNAs, Carbohydrate Metabolism, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
